EC50 of Dexmedetomidine in Deep Brain Stimulation Implantation of Patients With Parkinson's Disease
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Dexmedetomidine (DEX) sedation is widely used in deep brain stimulation implantation (DBSI)
of patients With Parkinson's disease. However, intraoperative application of DEX may affect
the discharge activity of deep brain nuclei and reduce the discharge frequency of Subthalamic
nucleus (STN) neurons. At present, there is still a lack of prospective intervention research
to explore the optimal dose that does not affect MER mapping in patients with Parkinson's
disease. The present study uses the Dixon and Massey up-and-down method to analyze the EC50
of DEX in patients with PD undergoing STN-DBS sedation, to clarify the balance meets the
sufficient comfort of patients without affecting the accurate target of MER and the optimal
dosage of DEX for boundary recognition.